Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients

NeuroTherapia, Inc.

Status and phase: Completed; Phase 3; Phase 2

Conditions: Hypogammaglobulinemia

Treatments: Drug: CMV-Ig

Study type: Interventional

Funder types: Other

Identifiers

NCT00137748

IRB2953

Details and patient eligibility

About

This is a randomized controlled trial of CMV-Ig in lung transplant recipients at the Cleveland Clinic Foundation who are hypogammaglobulinemic.

Full description

This is a randomized controlled trial of CMV-Ig in lung transplant recipients at the Cleveland Clinic Foundation who are hypogammaglobulinemic.

Enrollment: 50 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Lung transplant
• Hypogammaglobulinemia

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)